Log In
BCIQ
Print this Print this
 

IMO-9200

  Manage Alerts
Collapse Summary General Information
Company Idera Pharmaceuticals Inc.
DescriptionToll-like receptor 7 (TLR7), TLR8 and TLR9 antagonist
Molecular Target Toll-like receptor 7 (TLR7) ; Toll-like receptor 8 (TLR8)
Mechanism of ActionToll-like receptor 8 (TLR8) antagonist; Toll-like receptor 7 (TLR7) antagonist; Toll-like receptor 9 (TLR9) antagonist
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation
PartnerVivelix Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today